Sweden

OncoZenge

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

OncoZenge Secures Approximately SEK 70 Million in Financing Ahead of spin-off and separate listing

Lead Product(s): Bupivacaine

Therapeutic Area: Neurology Product Name: BupiZenge

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Baltic Sea Foundation

Deal Size: $8.3 million Upfront Cash: Undisclosed

Deal Type: Financing November 16, 2020

Details:

OncoZenge is developing the BUPI project under the BupiZenge ® brand , for the treatment of pain due to oral mucositis, a serious side effect of cancer treatment. BupiZenge ® has shown promising results in a phase 2 study. The capital will be used to finance the phase 3 study.

IRLAB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

IRLAB's Clinical Drug Candidate IRL752 Published in JPET

Lead Product(s): IRL752

Therapeutic Area: Neurology Product Name: IRL752

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

Details:

IRL752 is a drug candidate in clinical Phase II and is in development by IRLAB for the treatment of impaired balance (postural dysfunction) and falls in Parkinson's disease (PD-Falls).